US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. September 04, 2018

    Tribe Can't Fault Generics Cos. For Opioid Crisis, Court Told

    A group of generic-drug makers pushed back at a Montana tribe's attempt in multidistrict litigation ongoing in Ohio federal court to hold them liable for the opioid epidemic, saying they shouldn't be lumped in with their brand-name counterparts because they operate under a different business model.

  2. August 31, 2018

    Pharma Cases To Watch In 2018's Home Stretch

    Drugmakers in the closing months of 2018 may see pivotal rulings on novel efforts to hamstring rival medicines, escalating drama in multidistrict litigation over the opioid epidemic, and opening salvos in False Claims Act and drug-pricing fights at the U.S. Supreme Court. Here, Law360 summarizes key cases to watch.

  3. August 21, 2018

    Attys Relaunch Bid For 'Opioid Babies' Track In MDL

    Attorneys representing babies born to mothers who took prescription narcotics while pregnant renewed their push Tuesday for a separate track in the opioid multidistrict litigation, telling an Ohio federal judge that they're being stonewalled by the plaintiffs' executive committee.

  4. August 13, 2018

    States Push Back Against Dismissal Bids In Opioid MDL

    Dozens of states slammed a bid by drugmakers and distributor McKesson Corp. to dismiss claims that they fueled the opioid crisis, telling an Ohio federal judge who is overseeing the opioid multidistrict litigation that a state's ability to protect the health of its citizens must not be restricted.

  5. August 13, 2018

    Opioid MDL Bellwether Trial Postponed 6 Months

    An Ohio federal judge on Monday delayed the first bellwether trial in multidistrict litigation over the opioid epidemic by nearly six months to September 2019, the latest sign that dreams of quickly resolving the epic legal battle may not be realized.

  6. August 06, 2018

    Providers Say Don't Kill Hospital Bellwether In Opioid MDL

    A coalition of 44 hospitals that say they are on the front lines of treating the opioid epidemic on Friday asked to weigh in on multidistrict litigation over the opioid crisis, arguing that efforts to dismiss a bellwether lawsuit for hospitals should be rejected.

  7. August 02, 2018

    Allergan Files 3rd-Party Claims Against Pfizer In Opioid MDL

    Allergan Finance LLC has hit Pfizer Inc. and a subsidiary with third-party claims in multidistrict litigation over the opioid crisis, arguing that Allergan should be indemnified for having to defend pre-2009 misleading marketing allegations relating to a prescription opioid.

  8. August 01, 2018

    Opioid MDL Counties Get Partial Info From McKesson Report

    A special master appointed to oversee a discovery dispute in multidistrict litigation over the opioid crisis partially granted a request by counties for more information from a McKesson Corp. investigation into suspicious drug order oversight, finding Wednesday the counties are entitled to witness names but that statements and terms used in the investigation are protected work product.

  9. July 26, 2018

    Media Can't Access Drug Co. Data In Opioid MDL

    An Ohio federal judge on Thursday blocked media access to voluminous drug company data divulged in multidistrict litigation over the opioid crisis, concluding that publicity would undermine a delicate discovery process in the high-stakes case.

  10. July 25, 2018

    Discovery War Breaks Out In Opioid MDL Bellwethers

    A simmering discovery dispute in multidistrict litigation over the opioid crisis has boiled over, according to court filings late Tuesday that show drugmakers and pharmacies going public with heated objections over the "unprecedented breadth" and "massive scope" of document disclosures.